

US009593066B2

(12) United States Patent

Batra et al.

(54) PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN **REMODULIN®**

- (71) Applicant: United Therapeutics Corporation, Silver Spring, MD (US)
- (72) Inventors: Hitesh Batra, Herndon, VA (US); Sudersan M. Tuladhar, Silver Spring, MD (US); Raju Penmasta, Herndon, VA (US); David A. Walsh, Palmyra, VA (US)
- (73) Assignee: United Therapeutics Corporation, Silver Spring, MD (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 14/849,981
- Sep. 10, 2015 (22) Filed:

(65)**Prior Publication Data**

US 2015/0376106 A1 Dec. 31, 2015

Related U.S. Application Data

- (60) Division of application No. 13/933,623, filed on Jul. 2, 2013, now Pat. No. 9,156,786, which is a continuation of application No. 13/548,446, filed on Jul. 13, 2012, now Pat. No. 8,497,393, which is a continuation of application No. 12/334,731, filed on Dec. 15, 2008, now Pat. No. 8,242,305.
- (60) Provisional application No. 61/014,232, filed on Dec. 17, 2007.
- (51) Int. Cl.

C07C 59/72	(2006.01)
C07C 51/08	(2006.01)
C07C 51/41	(2006.01)
C07C 213/08	(2006.01)
C07C 405/00	(2006.01)
A01N 37/10	(2006.01)
C07C 39/12	(2006.01)
C07C 39/17	(2006.01)
C07C 59/60	(2006.01)

- (52) U.S. Cl. CPC C07C 59/72 (2013.01); C07C 51/08 (2013.01); C07C 51/41 (2013.01); C07C 51/412 (2013.01); C07C 213/08 (2013.01); C07C 405/0075 (2013.01); A01N 37/10 (2013.01); C07C 39/12 (2013.01); C07C 39/17 (2013.01); C07C 59/60 (2013.01)
- (58) Field of Classification Search CPC C07C 59/72; C07C 51/08; C07C 51/41; C07C 51/412; C07C 213/08; C07C

US 9,593,066 B2 (10) Patent No.:

(45) Date of Patent: *Mar. 14, 2017

(56)**References** Cited

U.S. PATENT DOCUMENTS

2 502 5		11/1052		
3,703,544			Morozowich	
3,888,916		6/1975		
4,306,075		12/1981	Aristoff	
4,306,076		12/1981	Nelson	
4,424,376		1/1984		
4,434,164		2/1984		
4,463,183		7/1984		
4,486,598			Aristoff	
4,544,764	Α	10/1985	Aristoff	
4,668,814	Α	5/1987	Aristoff	
4,683,330	Α	7/1987	Aristoff	
5,153,222	Α	10/1992	Tadepalli et al.	
5,466,713	Α	11/1995	Blitstein-Willinger et al.	
5,506,265	Α	4/1996	Blitstein-Willinger	
6,054,486	Α	4/2000	Crow et al.	
6,441,245	B1	8/2002	Moriarty et al.	
6,521,212	B1	2/2003	Cloutier et al.	
6,528,688	B2	3/2003	Moriarty et al.	
6,700,025	B2	3/2004	Moriarty et al.	
6,706,283	B1	3/2004	Appel et al.	
6,756,033	B2	6/2004	Cloutier et al.	
6,765,117	B2	7/2004	Moriarty et al.	
6,803,386	B2	10/2004	Shorr et al.	
6,809,223	B2	10/2004	Moriarty et al.	
7,199,157	B2	4/2007	Wade et al.	
7,384,978	B2	6/2008	Phares et al.	
7,417,070		8/2008	Phares et al.	
8,242,305	B2 *	8/2012	Batra C07C 51/08	
- , ,			562/466	
2001/0038855	A1	11/2001	Desjardin et al.	
2001/0056095		12/2001	Mylari	
(Continued)				

FOREIGN PATENT DOCUMENTS

CN	101891596 A	11/2010
CN	101891715 A	11/2010
	(Con	tinued)

OTHER PUBLICATIONS

Alexander et al., "The Synthesis of Benzindene Prostacyclin Analogs as Potential Antiulcer Agents," Prostaglandins, 1986, 32(5):647-653.

Aristoff et al., "Synthesis and Structure-Activity Relationship of Novel Stable Prostacyclin Analogs," Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Samuelsson et al., Eds., 1983, 11:267-274.

Aristoff et al., "Synthesis of Benzopyran Prostaglandins, Potent Stable Prostacyclin Analogs, Via an Intramolecular Mistunobu Reaction," Tetrahedron Letters, 1984, 25(36):3955-3958.

(Continued)

Primary Examiner - Yevegeny Valenrod

(74) Attorney, Agent, or Firm - Foley & Lardner LLP

(57) ABSTRACT

This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2002/0173672	A1 11/2002	Moriarty et al.
2004/0176645	A1 9/2004	Moriarty et al.
2005/0085540	A1 4/2005	Phares et al.
2005/0101608	A1 5/2005	Santel
2005/0165111	A1 7/2005	Wade et al.
2005/0282901	A1 12/2005	Phares et al.
2005/0282903	A1 12/2005	Wade et al.
2007/0078095	A1 4/2007	Phares et al.
2007/0078182	A1 4/2007	Phares et al.
2008/0200449	A1 8/2008	Olschewski et al.
2008/0249167	A1 10/2008	Phares et al.
2008/0280986	A1 11/2008	Wade et al.
2009/0036465	A1 2/2009	Roscigno et al.
2009/0163738	A1 6/2009	Batra et al.

FOREIGN PATENT DOCUMENTS

CN	2 710 726 A1	1/2012
EP	0 004 335 A2	10/1979
EP	0 087 237 B1	5/1986
EP	0 175 450 B1	3/1989
EP	0 159 784 B1	6/1989
EP	0 496 548 A1	7/1992
$_{\rm JP}$	56-122328 A	9/1981
JP	59-044340 A	3/1984
WO	WO 98/18452 A1	5/1998
WO	WO 98/39337 A1	9/1998
WO	WO 99/21830 A1	5/1999
WO	WO 03/070163 A2	8/2003
WO	WO 2005/007081 A2	1/2005
WO	WO 2007/134292 A2	11/2007
WO	WO 2008/100977 A2	8/2008
WO	WO 2009/117095 A1	9/2009
WO	WO 2012/009816 A1	1/2012

OTHER PUBLICATIONS

Aristoff et al., "Total Synthesis of a Novel Antiulcer Agent via a Modification of the Intramolecular Wadsworth-Emons-Wittig Reaction," J. Am. Chem. Soc., 1985, 107:7967-7974.

Batra et al., "Crystallization Process Development for a Stable Polymorph of Treprostinil Diethanolamine (UT-15C) by Seeding," Organic Process Research & Development, 2009, 13:242-249.

Belch et al., "Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Efficacy and Safety of AS-013, a Prostaglandin E1 Prodrug, in Patients with Intermittent Claudication," Circulation, May 6, 1997, 95(9):2298-2302.

Chemburkar et al., "Dealing with the Impact of Ritonavir Polymorphs on the Late Stages of Bulk Drug Process Development," Organic Process Research & Development, 2000, 4:413-417.

Chung et al., "Promoters for the (Alkyne)hexacarbonyldicobalt-Based Cyclopentenone Synthesis," Organometallics, 1993, 12:220-223

Clark et al., "High-Performance Liquid Chromatographic Method for Determining the Enantiomeric Purity of a Benzindene Prostaglandin by a Diastereomeric Separation," Journal of Chromatography, 1987, 408:275-283.

Hardinger et al., "Triply-Convergent Syntheses of Two Homochiral Arene-Fused Prostacyclin Analogs Related to U68,215," Bioorganic & Medicinal Chemistry Letters, 1991, 1(1):79-82.

Hicks et al., "A Practical Titanium-Catalyzed Synthesis of Bicyclic Cyclopentenones and Allylic Amines," J. Org. Chem., 1996, 61:2713-2718.

Jeong et al., "Catalytic Version of the Intramolecular Pauson-Khand Reaction," J. Am. Chem. Soc., 1994, 116:3159-3160.

Khand et al., "Organocobalt Complexes. Part II. Reaction of Acetylenehexacarbonyl-dicobalt Complexes, (R¹ C₂ R²)Co₂

Mathre et al., "A Practical Enantioselective Synthesis of α,α -Diaryl-2-pyrrolidinemethanol. Preparation and Chemistry of the Corresponding Oxazaborolidines," J. Org. Chem., 1991, 56:751-762.

Moriarty et al., "The Intramolecular Asymmetric Pauson-Khand Cyclization as a Novel and General Stereoselective Route to Benzindene Prostacyclins: Synthesis of UT-15 (Treprostinil)," *J. Org. Chem.* 2004, 69, 1890-1902.

Mulzer et al., "Asymmetric Synthesis of Carbacyclin Precursors by Pauson-Khand Cyclization," Liebigs Ann. Chem., 1988, 891-897. Nelson, Norman A., "Prostaglandin Nomenclature," J. Med. Chem., Sep. 1974, 17(9):911-918.

Pagenkopf et al., "Photochemical Promotion of the Intramolecular Pauson-Khand Reaction. A New Experimental Protocol for Cobalt-Catalyzed [2 + 2 + 1] Cycloadditions," J. Am. Chem. Soc., 1996, 118:2285-2286.

Pagenkopf, Brian L., "Substrate and Reagent Control of Diastereoselectivity in Transition Metal-Mediated Process: Development of a Catalytic Photo Promoted Pauson-Khand Reaction," Diss. Abstr. Int., 57(12)7535, 1977, Abstract.

Patterson et al., "Acute Hemodynamic Effects of the Prostacyclin Analog 15AU81 in Severe Congestive Heart Failure," Am. J. Cardio., 1995, 75:26A-33A.

Paulson, Peter L., "The Khand Reaction," Tetrahedron, 1985, 41(24):5855-5860.

Schore, Neil E., "Transition-Metal-Mediated Cycloaddition Reactions of Alkynes in Organic Synthesis," Chem. Rev., 1988, 88:1081-1119.

Shambayati et al., "N-Oxide Promjoted Pauson-Khand Cyclizations at Room Temperature," Tetrahedron Letters, 1990, 31(37):5289-5292.

Snell et al., "Investigating the Effect of Impurities on Macromolecule Crystal Growth in Microgravity," Crystal Growth & Design, 2001, 1(2):151-158.

Sorbera et al. "UT-15. Treatment of Pulmonary Hypertension Treatment of Peripheral Vascular Disease," *Drug of the Future*, 2001, 26(4), 364-374.

Takano et al., "Enantiodivergent Synthesis of Both Enantiomers of Sulcatol and Matsutake Alcohol from (R)-Epichlorohydrin," Chemistry Letters, 1987, 2017-2020.

Viedma, Cristobal, "Selective Chiral Symmetry Breaking during Crystallization: Parity Violation of Cryptochiral Environment in Control?" Crystal Growth & Design, 2007, 7(3):553-556.

Whittle et al., "Antithrombotic Assessment and Clinical Potential of Prostacyclin Analogues," Progress in Medicinal Chemistry, Ellis et al. Eds., 1984, Chapter 6, vol. 21, 238-279.

Zhang et al., "A Nickel(0)-Catalyzed Process for the Transformation of Enynes to Bicyclic Cyclopentenones," J. Org. Chem., 1996, 61:4498-4499.

Steadymed Ltd., v. United Therapeutics Corporation, Petition for Inter Partes Review of U.S. Pat. No. 8,497,393, under 37 CFR 42.100, dated Oct. 1, 2015, with Exhibits 1009, 1010, 1017 and 1018.

Ege, S., Organic Chemistry Second Edition, 1989, 541-547.

Schoffstall et al., *Microscale and Miniscale Organic Chemistry* Laboratory Experiments, 2nd. Ed., 2004, 200-202.

Wiberg, Kenneth, Laboratory Technique in Organic Chemistry, 1960, 112.

Bighley et al., "Salt Forms of Drugs and Absorption," Encyclopedia of Pharmaceutical Technology, Swarbrick et al., Eds., 1995, 13:453-499.

Simonneau et al., "Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue in Patients with Pulmonary Arterial Hypertension," Am. J. Respir. Crit. Care Med., 2002, 165:800-804.

Redacted Petitioner's Reply to Patent Owner's Response to Petition filed on Sep. 27, 2016 in *Steadymed Ltd. (Petitioner)*, v. *United Therapeutics Corporation (Patent Owner)*, Case IPR2016-00006, U.S. Pat. No. 8,497,393, with Exhibits 1022-1028.

Petitioner's Demonstratives filed Nov. 28, 2016, in Steadymed Ltd.

(56) **References Cited**

OTHER PUBLICATIONS

Patent Owner Response to Petition filed Nov. 23, 2016, in *Steadymed Ltd. (Petitioner)*, v. *United Therapeutics Corporation (Patent Owner)*, Case IPR2016-00006, U.S. Pat. No. 8,497,393, with Redacted Exhibits 2006, 2020, 2022, 2058 and 2059 filed Nov. 23, 2016, 1151 pages.

Patent Owner Demonstratives filed Nov. 23, 2016, in *Steadymed Ltd. (Petitioner)*, v. *United Therapeutics Corporation (Patent Owner)*, Case IPR2016-00006, U.S. Pat. No. 8,497,393, 62 pages. Decision Redacted Institute of *Inter Partes* Review dated Nov. 23, 2016, in *Steadymed Ltd. (Petitioner)*, v. *United Therapeutics Corporation (Patent Owner)*, Case IPR2016-00006, U.S. Pat. No. 8,497,393, 53 pages.

Service Third Party Submission dated Oct. 16, 2016, filed but not entered in U.S. Appl. No. 14/849,981 on Oct. 16, 2016, with 6 indicated attachments, 822 pages.

Redacted Defendant Sandoz Inc.'s Invalidity Contentions dated Feb. 5, 2015, *United Therapeutics Corporation* (Plaintiff) v. *Sandoz Inc.* (Defendant), In The United States District Court for the District of New Jersey, Civil Action No. 3:14-cv-5499(PGH)(LHG), 90 pages.

Defendant Sandoz Inc.'s Invalidity Contention Chartss dated Feb. 5, 2015, *United Therapeutics Corporation* (Plaintiff) v. *Sandoz Inc.* (Defendant), In The United States District Court for the District of New Jersey, Civil Action No. 3:14-cv-5499(PGH)(LHG), 189 pages.

Defendant Actavis Laboratories FL, Inc. Preliminary Invalidity Contentions, dated Aug. 30, 2016, *United Therapeutics Corporation, and Supemus Pharmaceuticals, Inc.*, (Plaintiff) v. Actavis Laboratories FL, Inc., (Defendant), In The United States District Court for the District of New Jersey, Civil Action No. 3:16-cv-01816-PGS-LHG, Civil Action No. 3:16-cv-03642-PGS-LHG, 330 pages, (see particularly pp. 18-20, 42-62 and 269-280).

Exhibit G, Invalidity Claim Chart for the '393 patent, Jan. 12, 2015, 66 pages.

Defendant Teva Pharmaceuticals USA, Inc.'s Amended Non-Infringement and Invalidity Contentions, dated Apr. 24, 2015, *United Therapeutics Corporation* (Plaintiff) v. *Teva Pharmaceuticals USA, Inc.* (Defendant), In The United States District Court for the District of New Jersey, Civil Action No. 3:14-cv-05498(PGS)(LHG), 94 pages, (see particularly pp. 22-54).

Arumugan et al., "A New Purification Process for Pharmaceutical and Chemical Industries," Organic Process Research & Development, 2005, 9:319-320.

DOCKE.

RM

Burk et al., "An Enantioselective Synthesis of (S)-(+)-3-Aminomethyl-5-methylhexanoic Acid via Asymmetric Hydrogenation," J. Org. Chem., 2003, 68:5731-5734.

Eliel et al., Stereochemistry of Organic Compounds, 1994, 322-325. Harwood et al., Experimental organic chemistry: Principles and Practice, 1989, 127-134.

Jones, Maitland Jr., Organic Chemistry, 2nd Ed., 2000, 153-155.

Lin et al., "Benzindene Prostaglandins. Synthesis of Optically Pure 15-Deoxy-U-68,215 and Its Enantiomer via a Modified Intramolecular Wadsworth-Emmons-Wittig Reaction," J. Org. Chem., 1987, 52:5594-5601.

McManus et al., "Tetrazole Analogs of Plant Auxins," J. Org. Chem., 1959, 24:1464-1467.

Monson, Richard S., Advanced Organic Synthesis, Methods and Techniques, 1971, 178-188.

Ohno et al., "Development of Dual-Acting Benzofurans for Thromboxane A2 Receptor Antagonist and Prostacyclin Receptor Agonist: Synthesis, Structure-Activity Relationship, and Evaluation of Benzofuran Derivatives," J. Med. Chem., 2005, 48:5279-5294. Olmsted III et al., Chemistry, The Molecular Science, Mosby-Year Book, Inc., Chapter 10 "Effects of Intermolecular Forces," 1994, 428-486.

Pavia et al., Introduction to Organic Laboratory Techniques, First Edition, 1998, 648.

Physicians' Desk Reference, 59 Edition, 2005, for Bicillin® L-A (penicillin G benzathine suspension), 5 pages.

Priscinzano et al., "Piperidine Analogues of 1-[2-[Bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine (GBR 12909): High Affinity Ligands for the Dopamine Transporter," J. Med. Chem., 2002, 45:4371-4374.

Remodulin® label, 2014, 17 pages.

Schoffstall, et al., Microscale and Miniscale Organic Chemistry Laboratory Experiments, 2004, 2nd Ed., 200-202.

Sorrell, Thomas N., Organic Chemistry, 1999, 755-758.

Wiberg, Laboratory Technique in Organic Chemistry, 1960, 112.

Yu et al., "Novel Synthetic Route of a Pivotal Intermediate for the Synthesis of 1 β -Methyl Carbapenem Antibiotics," Organic Process Research & Development, 2006,10:829-832.

Redacted Defendant Watson Laboratories, Inc.'s Invalidity Contentions dated Dec. 11, 2015, *United Therapeutics Corporation* (Plaintiff) v. *Watson Laboratories, Inc.* (Defendant), In The United States District Court for the District of New Jersey, Civil Action No. 3:15-cv-05723-PGS-LHG, 35 pages.

* cited by examiner

5

PROCESS TO PREPARE TREPROSTINIL, THE ACTIVE INGREDIENT IN **REMODULIN®**

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Divisional of U.S. application Ser. No. 13/933,623, filed Jul. 2, 2013, which is a Continuation 10of U.S. application Ser. No. 13/548,446, filed Jul. 13, 2012, which is a Continuation of U.S. application Ser. No. 12/334, 731, filed Dec. 15, 2008, which claims priority from U.S. Provisional Patent Application 61/014,232, filed Dec. 17, 2007, the entire contents of which are incorporated herein by 15reference.

BACKGROUND

The present invention relates to a process for producing 20 prostacyclin derivatives and novel intermediate compounds useful in the process.

Prostacyclin derivatives are useful pharmaceutical compounds possessing activities such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, and 25 lating agent to produce a compound of formula III, bronchodilation.


Treprostinil, the active ingredient in Remodulin®, was first described in U.S. Pat. No. 4,306,075. Treprostinil, and other prostacyclin derivatives have been prepared as described in Moriarty, et al in J. Org. Chem. 2004, 69, 30 1890-1902, Drug of the Future, 2001, 26(4), 364-374, U.S. Pat. Nos. 6,441,245, 6,528,688, 6,765,117 and 6,809,223. Their teachings are incorporated by reference to show how to practice the embodiments of the present invention.

35 U.S. Pat. No. 5,153,222 describes use of treprostinil for treatment of pulmonary hypertension. Treprostinil is approved for the intravenous as well as subcutaneous route, the latter avoiding septic events associated with continuous intravenous catheters. U.S. Pat. Nos. 6,521,212 and 6,756, 40 033 describe administration of treprostinil by inhalation for treatment of pulmonary hypertension, peripheral vascular disease and other diseases and conditions. U.S. Pat. No. 6,803,386 discloses administration of treprostinil for treating cancer such as lung, liver, brain, pancreatic, kidney, 45 prostate, breast, colon and head-neck cancer. U.S. patent application publication No. 2005/0165111 discloses treprostinil treatment of ischemic lesions. U.S. Pat. No. 7,199,157 discloses that treprostinil treatment improves kidney functions. U.S. patent application publication No. 2005/0282903 50 discloses treprostinil treatment of neuropathic foot ulcers. U.S. application Ser. No. 12/028,471 filed Feb. 8, 2008, discloses treprostinil treatment of pulmonary fibrosis. U.S. Pat. No. 6,054,486 discloses treatment of peripheral vascular disease with treprostinil. U.S. patent application Ser. No. 55 11/873,645 filed Oct. 17, 2007 discloses combination therapies comprising treprostinil. U.S. publication No. 2008/ 0200449 discloses delivery of treprostinil using a metered dose inhaler. U.S. publication No. 2008/0280986 discloses treatment of interstitial lung disease with treprostinil. U.S. 60 application Ser. No. 12/028,471 filed Feb. 8, 2008 discloses treatment of asthma with treprostinil. U.S. Pat. Nos. 7,417, 070, 7,384,978 and U.S. publication Nos. 2007/0078095, 2005/0282901, and 2008/0249167 describe oral formulations of treprostinil and other prostacyclin analogs. 65


need exists for an efficient process to synthesize these compounds on a large scale suitable for commercial production.

SUMMARY

The present invention provides in one embodiment a process for the preparation of a compound of formula I, hydrate, solvate, prodrug, or pharmaceutically acceptable salt thereof.



The process comprises the following steps: (a) alkylating a compound of structure II with an alky-



wherein

w=1, 2, or 3; Y₁ is trans-CH=CH-, cis-CH=CH-, -CH₂(CH₂) $_{m}$ —, or —C==C—; m is 1, 2, or 3;

 $R_{7} 1 S$

- (1) $-C_pH_{2p}$ -CH₃, wherein p is an integer from 1 to 5, inclusive,
- (2) phenoxy optionally substituted by one, two or three chloro, fluoro, trifluoromethyl, (C1-C3)alkyl, or (C1-C₃)alkoxy, with the proviso that not more than two substituents are other than alkyl, with the proviso that R_7 is phenoxy or substituted phenoxy, only when R_3 and R_4 are hydrogen or methyl, being the same or different.
- (3) phenyl, benzyl, phenylethyl, or phenylpropyl optionally substituted on the aromatic ring by one, two or three chloro, fluoro, trifluoromethyl, (C_1-C_3) alkyl, or (C_1-C_3) alkoxy, with the proviso that not more than two substituents are other than alkyl,
- (4) cis-CH=CH-CH₂-CH₃,

Find authenticated court documents without watermarks at docketalarm.com.


5


35

wherein $-C(L_1)-R_2$ taken together is


- (1) (C₄-C₇)cycloalkyl optionally substituted by 1 to 3 (C₁-C₅)alkyl;
- (2) 2-(2-furyl)ethyl,
- (3) 2-(3-thienyl)ethoxy, or
- (4) 3-thienyloxymethyl;
- $\begin{array}{l} M_1 \text{ is } \alpha \text{-OH:} \beta \text{-} R_5 \text{ or } \alpha \text{-} R_5 \text{:} \beta \text{-OH or } \alpha \text{-} OR_2 \text{:} \beta \text{-} R_5 \text{ or } \alpha \text{-} R_5 \text{:} \\ \beta \text{-} OR_2, \text{ wherein } R_5 \text{ is hydrogen or methyl, } R_2 \text{ is an} \\ \text{ alcohol protecting group, and} \\ \end{array}$
- L₁ is α -R₃: β -R₄, α -R₄: β -R₃, or a mixture of α -R₃: β -R₄ and α -R₄: β -R₃, wherein R₃ and R₄ are hydrogen, methyl, or fluoro, being the same or different, with the proviso that one of R₃ and R₄ is fluoro only when the other is hydrogen or fluoro.
- (b) hydrolyzing the product of step (a) with a base,

(c) contacting the product of step (b) with a base B to for a salt of formula $I_{\rm s}$






(b) hydrolyzing the product of step (a) with a base,(c) contacting the product of step (b) with a base B to for a salt of formula IV_s, and




(d) reacting the salt from step (c) with an acid to form the compound of formula I.

The present invention provides in another embodiment a process for the preparation of a compound of formula IV.



The process comprises the following steps:

(a) alkylating a compound of structure V with an alkylating agent to produce a compound of formula VI,



(d) reacting the salt from step (b) with an acid to form the compound of formula IV.

DETAILED DESCRIPTION

The various terms used, separately and in combinations, in the processes herein described are defined below.

The expression "comprising" means "including but not limited to." Thus, other non-mentioned substances, additives, carriers, or steps may be present. Unless otherwise specified, "a" or "an" means one or more.

 C_{1-3} -alkyl is a straight or branched alkyl group containing 1-3 carbon atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, and isopropyl.

C₁₋₃-alkoxy is a straight or branched alkoxy group con taining 1-3 carbon atoms. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, and isopropoxy.

 C₄₋₇-cycloalkyl is an optionally substituted monocyclic, bicyclic or tricyclic alkyl group containing between 4-7 carbon atoms. Exemplary cycloalkyl groups include but not
55 limited to cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.

Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers 60 to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein.

As used herein, the term "prodrug" means a derivative of 65 a compound that can hydrolyze, oxidize, or otherwise react

Find authenticated court documents without watermarks at docketalarm.com.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.